~~<i id='FA9A530AFC'><strike id='FA9A530AFC'><tt id='FA9A530AFC'><pre id='FA9A530AFC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：knowledge 2025-10-02 22:23:51 - browse：8186

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Readout LOUD podcast: Merger Mondays, Ozempic panic

knowledge

explore

leisure time

focus

explore

SamuelCorum/GettyImagesTheDepartmentofJusticehasaskedafederaljudgetodismissalawsuitbroughtbyHumana,w

WSS

Better Therapeutics data on benefit with GLP

How clinical AI models' predictive power can degrade over time

Peter Marks talks Operation Warp Speed for Rare Diseases

STAT Readout Newsletter: Today in biotech, life science news

A revolution in caring for preterm infants

Cancer cells are shown to suck energy source from immune cells

hotspot

focus

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

What the Wegovy shortage looks like for doctors — and for patients

Anesthesiologist group: stop taking Ozempic before surgery

What the Wegovy shortage looks like for doctors — and for patients

Affirmative action in medical school literally saved lives

Christmas in the PICU brings some surprising joy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How to keep neuroscience’s past racism from being its future

Cancer drug shortages should be causing more outrage

Humana CEO Bruce Broussard to step down in 2024

explore

Three trends to watch in biotech in 2024

HCA sued by state AG for quality issues at Mission Health

Medicare Advantage beneficiaries sue Humana over algorithm use

Why health records don't always know when patients are dead

Takeaways from AdvaMed, the largest medical devices conference

In Spain, a hospital brews its own CAR

leisure time

focus

explore

explore